BR112015008170A2 - cristal mono-hidratado de sal de potássio fimasartana, método para a preparação do mesmo e composição farmacológica compreendendo o mesmo - Google Patents
cristal mono-hidratado de sal de potássio fimasartana, método para a preparação do mesmo e composição farmacológica compreendendo o mesmoInfo
- Publication number
- BR112015008170A2 BR112015008170A2 BR112015008170A BR112015008170A BR112015008170A2 BR 112015008170 A2 BR112015008170 A2 BR 112015008170A2 BR 112015008170 A BR112015008170 A BR 112015008170A BR 112015008170 A BR112015008170 A BR 112015008170A BR 112015008170 A2 BR112015008170 A2 BR 112015008170A2
- Authority
- BR
- Brazil
- Prior art keywords
- potassium salt
- pharmaceutical composition
- preparation
- same
- fimasartan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120113848A KR101490329B1 (ko) | 2012-10-12 | 2012-10-12 | 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물 |
| PCT/KR2013/009097 WO2014058268A1 (ko) | 2012-10-12 | 2013-10-11 | 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015008170A2 true BR112015008170A2 (pt) | 2017-07-04 |
Family
ID=50477658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015008170A BR112015008170A2 (pt) | 2012-10-12 | 2013-10-11 | cristal mono-hidratado de sal de potássio fimasartana, método para a preparação do mesmo e composição farmacológica compreendendo o mesmo |
Country Status (13)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101545268B1 (ko) * | 2015-02-05 | 2015-08-20 | 보령제약 주식회사 | 정제 및 이의 제조방법 |
| CN105784867B (zh) * | 2016-03-28 | 2019-01-01 | 北京睿创康泰医药研究院有限公司 | 用于分析非马沙坦有关物质的hplc方法及这些杂质作参比标准的用途 |
| KR102247408B1 (ko) | 2017-09-18 | 2021-05-03 | 보령제약 주식회사 | 피마살탄 프로드러그 |
| KR102402501B1 (ko) * | 2018-04-24 | 2022-05-26 | (주)국전약품 | 피마살탄 트로메타민염 및 이를 포함하는 약제학적 조성물 |
| KR102221856B1 (ko) | 2020-10-12 | 2021-03-02 | 유니셀랩 주식회사 | 신규한 피마살탄 결정형의 다형체 |
| KR20230062916A (ko) | 2021-11-01 | 2023-05-09 | 그린케미칼 주식회사 | 피마살탄 무수물 a형 결정다형 및 그 제조방법 |
| KR20230062917A (ko) | 2021-11-01 | 2023-05-09 | 그린케미칼 주식회사 | 피마살탄 일수화물 b형 결정다형 및 그 제조방법 |
| KR20240146734A (ko) | 2023-03-30 | 2024-10-08 | (주) 에프엔지리서치 | 피마살탄의 신규 염 및 이의 제조방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100300566B1 (ko) * | 1994-09-17 | 2001-11-22 | 조생현 | 피리미디논유도체와그의제조방법및용도 |
| KR19990081093A (ko) * | 1998-04-25 | 1999-11-15 | 조생현 | 피리미디논 화합물, 이를 함유하는 약제학적 조성물 및 이의제조방법 |
| KR100617953B1 (ko) | 2000-03-23 | 2006-08-30 | 보령제약 주식회사 | 피리미디논 화합물 및 이의 염의 제조방법 |
| MXPA04002653A (es) * | 2001-09-21 | 2004-07-08 | Boryung Pharm | Metodo para preparar compuestos de pirimidinona y sales farmaceuticamente aceptables del mismo. |
| KR100521980B1 (ko) * | 2002-10-10 | 2005-10-17 | 보령제약 주식회사 | 피리미디논 화합물 및 이의 염의 삼수화물의 제조 방법 |
| CA2832758C (en) * | 2011-04-12 | 2015-12-15 | Boryung Pharmaceutical Co., Ltd. | Antihypertensive pharmaceutical composition |
-
2012
- 2012-10-12 KR KR20120113848A patent/KR101490329B1/ko active Active
-
2013
- 2013-10-11 IN IN3975DEN2015 patent/IN2015DN03975A/en unknown
- 2013-10-11 CA CA2887056A patent/CA2887056C/en not_active Expired - Fee Related
- 2013-10-11 WO PCT/KR2013/009097 patent/WO2014058268A1/ko active Application Filing
- 2013-10-11 BR BR112015008170A patent/BR112015008170A2/pt not_active Application Discontinuation
- 2013-10-11 AU AU2013330603A patent/AU2013330603B2/en not_active Ceased
- 2013-10-11 EP EP13845572.0A patent/EP2927226A4/en not_active Withdrawn
- 2013-10-11 RU RU2015117524A patent/RU2613555C2/ru active
- 2013-10-11 CN CN201380063465.5A patent/CN104854099B/zh not_active Expired - Fee Related
- 2013-10-11 MX MX2015004573A patent/MX353635B/es active IP Right Grant
- 2013-10-11 MY MYPI2015000875A patent/MY169064A/en unknown
-
2015
- 2015-04-10 PH PH12015500794A patent/PH12015500794A1/en unknown
- 2015-04-12 SA SA515360275A patent/SA515360275B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY169064A (en) | 2019-02-12 |
| RU2015117524A (ru) | 2016-12-10 |
| IN2015DN03975A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-10-02 |
| MX353635B (es) | 2018-01-22 |
| CN104854099A (zh) | 2015-08-19 |
| AU2013330603A1 (en) | 2015-05-28 |
| EP2927226A1 (en) | 2015-10-07 |
| AU2013330603B2 (en) | 2016-03-31 |
| RU2613555C2 (ru) | 2017-03-17 |
| CA2887056A1 (en) | 2014-04-17 |
| CN104854099B (zh) | 2016-11-16 |
| WO2014058268A1 (ko) | 2014-04-17 |
| MX2015004573A (es) | 2015-07-21 |
| SA515360275B1 (ar) | 2017-07-11 |
| KR101490329B1 (ko) | 2015-02-04 |
| CA2887056C (en) | 2017-09-05 |
| KR20140047483A (ko) | 2014-04-22 |
| EP2927226A4 (en) | 2016-07-13 |
| PH12015500794A1 (en) | 2015-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015008170A2 (pt) | cristal mono-hidratado de sal de potássio fimasartana, método para a preparação do mesmo e composição farmacológica compreendendo o mesmo | |
| BR112014014184A2 (pt) | triazolopiridinas substituídas e seu uso como inibidores de ttk | |
| BR112015000615A8 (pt) | Purinas macrocíclicas para o tratamento de infecções virais e composição farmacêutica que as compreende | |
| BR112015002372A2 (pt) | composições e métodos para a redução do teor de álcool no sangue | |
| BR112014013085A2 (pt) | forma cristalina do ticagrelor, processo para a preparação da forma cristalina do ticagrelor, composição farmacêutica e processo para preparar uma composição farmacêutica | |
| CL2014000183A1 (es) | Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación. | |
| BR112015003591A8 (pt) | Usos de lys-c e métodos para fabricação de um polipeptídeo proteoliticamente processado | |
| PE20151979A1 (es) | Compuestos quimicos | |
| BR112016011170A8 (pt) | derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica | |
| EA029539B8 (ru) | Фармацевтическая композиция ситаглиптина | |
| BR112014017481A8 (pt) | formulação em pó seco para uso em um inalador de pó seco, inalador de pó seco e uso de uma formulação | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| BR112013029730A2 (pt) | composição farmacêutica de rosuvastatina cálcica | |
| BR112015028096A2 (pt) | forma cristalina de um hidrato, processo para a preparação da forma cristalina, composição farmacêutica, forma cristalina, combinação farmacêutica, hidrato cristalino e cristais | |
| BR112014018767A8 (pt) | Compostos de pirroldicarboxamidas fundidas e composição farmacêutica que os compreende | |
| IN2014MN01465A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| GEP201706637B (en) | Co-micronisation product comprising ulipristal acetate | |
| CL2015002712A1 (es) | Cristales de laquinimod sódico y proceso para la preparación de ellos | |
| BR112013026698A2 (pt) | formulações do tipo tópica compreendendo depsipeptídeo cíclico | |
| BR112015030774A2 (pt) | novos compostos para o tratamento de câncer | |
| BR112013004562A2 (pt) | 2-óxi-quinolina-3-carboxamidas substituídas como moduladores kcnq2/3 | |
| BR112014015841A2 (pt) | composição de resina alquídica compreendendo sílica | |
| BR112015002429A2 (pt) | processo para a preparação de pemetrexede e sal de lisina do mesmo | |
| BR112014009760A2 (pt) | análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo | |
| BR112015014137B8 (pt) | Composição com alto teor de fexofenadina e processo para a preparação da mesma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |